MAPT and Alzheimer disease: GluR4 was recently identified as a biomarker that demonstrates preclinical changes in AD patients before neurodegeneration and Tau pathology, although the diagnostic and prognostic value of this AMPA receptor complex protein remains to be evaluated in depth [5, 7].